Open an account

Mustang Bio

MBIO · NASDAQ

$0.3795+$0.0065 (+1.74%)TodayMarket closed ·
Prev close $0.373

About MBIO

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company is headquartered in Waltham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2017-08-22. The firm has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. The company is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. The company has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.

Employees
4
Headquarters
Waltham, Massachusetts
Listed
Aug 22, 2017
Sector
Health Care
Industry
Biotechnology
Website
mustangbio.com

MBIO key statistics

Market cap
2.88M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
42.59K
Volume
10.21K
Open price
$0.3701
High today
$0.388
Low today
$0.3701
52 Week high
$1.69
52 Week low
$0.3701

Mustang Bio (MBIO) at a glance

Mustang Bio (MBIO) last traded at $0.3795, with a market cap of 2.88M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.3701 and $0.388. The current price is 2.5% above the day's low and 2.2% below its high.

Volume so far is 10.21K shares, below the average of 42.59K shares a day.

Over the past year Mustang Bio has ranged from $0.3701 to $1.69, and now sits 1% of the way up that range.

Mustang Bio met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q4 FY24 it reported -$37.95 per share against an estimate of -$8.16.

MBIO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 31.7% on average.

  1. Q3 FY22: reported -$135.00 per share against an estimate of -$151.09
  2. Q4 FY22: reported -$135.00 per share against an estimate of -$147.26
  3. Q1 FY23: reported -$103.00 per share against an estimate of -$153.51
  4. Q2 FY23: reported -$100.00 per share against an estimate of -$92.18
  5. Q3 FY23: reported -$70.00 per share against an estimate of -$65.03
  6. Q4 FY23: reported -$43.00 per share against an estimate of -$67.83
  7. Q3 FY24: reported -$2.00 per share against an estimate of -$6.63
  8. Q4 FY24: reported -$37.95 per share against an estimate of -$8.16

MBIO news

  • Mohd Haider

    Calidi Biotherapeutics Stock Jumps 39% After Hours — What's Going On

  • Press releaseGlobe Newswire

    Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

  • Henry Khederian

    Mustang Bio (MBIO) Stock Explodes 260% After FDA Grants Key Cancer Drug Designation

  • Avi Kapoor

    Dow Dips 1%; Mustang Bio Shares Spike Higher

  • Avi Kapoor

    Nasdaq Falls Over 100 Points; Capgemini To Acquire WNS

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Avi Kapoor

    US Stocks Mixed; UniFirst Shares Fall After Q3 Results

  • Avi Kapoor

    Why Greenbrier Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket

Similar companies

Companies in the same industry as Mustang Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.